Mapping FACT-P and EORTC QLQ-C30 to patient health status measured by EQ-5D in metastatic hormone-refractory prostate cancer patients.
about
Review of studies mapping from quality of life or clinical measures to EQ-5D: an online databaseComparison of methods to estimate health state utilities for ovarian cancer using quality of life data: a Gynecologic Oncology Group studyMapping CushingQOL scores to EQ-5D utility values using data from the European Registry on Cushing's syndrome (ERCUSYN).Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma.Mapping the SRS-22r questionnaire onto the EQ-5D-5L utility score in patients with adolescent idiopathic scoliosis.Longitudinal predictive ability of mapping models: examining post-intervention EQ-5D utilities derived from baseline MHAQ data in rheumatoid arthritis patients.Mapping the FACT-G cancer-specific quality of life instrument to the EQ-5D and SF-6D.From KIDSCREEN-10 to CHU9D: creating a unique mapping algorithm for application in economic evaluationMapping the functional assessment of cancer therapy-breast (FACT-B) to the 5-level EuroQoL Group's 5-dimension questionnaire (EQ-5D-5L) utility index in a multi-ethnic Asian population.Mapping FACT-P to EQ-5D in a large cross-sectional study of metastatic castration-resistant prostate cancer patients.Mapping Functions in Health-Related Quality of Life: Mapping from Two Cancer-Specific Health-Related Quality-of-Life Instruments to EQ-5D-3L.Estimating health-state utility values for patients with recurrent ovarian cancer using Functional Assessment of Cancer Therapy - General mapping algorithmsMapping CushingQoL scores onto SF-6D utility values in patients with Cushing's syndrome.Converting condition-specific measures into preference-based outcomes for use in economic evaluation.Health-state utility values in breast cancer.Evaluation of content on EQ-5D as compared to disease-specific utility measures.Mapping utilities from cancer-specific health-related quality of life instruments: a review of the literature.The cost-effectiveness of active surveillance compared to watchful waiting and radical prostatectomy for low risk localised prostate cancerHealth-related quality of life effects of enzalutamide in patients with metastatic castration-resistant prostate cancer: an in-depth post hoc analysis of EQ-5D data from the PREVAIL trial.Mapping CHU9D Utility Scores from the PedsQLTM 4.0 SF-15.Certolizumab Pegol for Treating Rheumatoid Arthritis Following Inadequate Response to a TNF-α Inhibitor: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.Prostate cancer: how assessment of QoL can improve delivery of care.Mapping algorithms from QLQ-C30 to EQ-5D utilities: no firm ground to stand on yet.Health-related quality of life among prostate cancer patients: real-life situation at the beginning of treatment.Mapping health-related quality of life scores from FACT-G, FAACT, and FACIT-F onto preference-based EQ-5D-5L utilities in non-small cell lung cancer cachexia.The potential for a generally applicable mapping model between QLQ-C30 and SF-6D in patients with different cancers: a comparison of regression-based methods.Pain questionnaire performance in advanced prostate cancer: comparative results from two international clinical trials.Mapping the cancer-specific EORTC QLQ-C30 and EORTC QLQ-BR23 to the generic EQ-5D in metastatic breast cancer patients.Responsiveness and minimal important score differences in quality-of-life questionnaires: a comparison of the EORTC QLQ-C30 cancer-specific questionnaire to the generic utility questionnaires EQ-5D and 15D in patients with multiple myeloma.Health utility and economic analysis: theoretical and practical issues.
P2860
Q27026613-3BCC29C7-B961-4346-A1CF-698F10EE4949Q30415018-B666ACB7-5369-4AE5-B227-B46AC9C972F3Q30608673-2BE45E54-F6DF-4303-B8AE-B8F228E30AB6Q33557934-983DBCFB-75C6-4B8C-9473-F5DE154A5A27Q33570682-D97A4FB0-8DF7-4F85-AF8D-59696EA8F652Q34129848-A069DC94-3AF3-4EC8-8103-60F3BA3D080BQ34455288-696C7F63-8E41-4953-9C1B-8FC6D534ACF2Q34570162-436174E0-C38E-4EC7-B9F6-90BB0DA9C316Q34707998-0F5452F7-29F1-4AC8-82CC-166DC7EA359FQ35148246-F6A0B4E8-15D5-49E8-939B-0BA6B5589156Q36070909-47C2A2B4-190E-4302-B2A2-D11AF8187C45Q36332234-8618DC2B-FB19-4F79-8BAF-A8D8C85272D1Q36872749-E31F71C8-B3B4-4242-B1C2-EF622E4EA0DBQ37763123-1E764CDD-9A0C-4E1E-874E-5D51192FB29FQ37800481-9EEA6E1A-8C4A-440C-8699-3A5BC1F57C5CQ38021389-D1D19A26-5B56-4A24-B449-488100A75F1BQ38161920-2480D5F8-677A-4465-9E86-F0D9FED79C89Q38633574-035469D9-7F08-4E08-AB9A-C7559C9217DAQ38667426-D4E192F8-A5AE-4551-BAF9-9FBE6E531FEAQ39121036-28FA7A45-5998-4224-B86A-29058061561DQ39333743-FBD09776-ECC3-480D-8A6D-F8AF2B40278EQ42876402-5CFFB489-247E-4635-8CD6-82A3F22134CAQ43588238-9627C48B-A82D-4AB0-905D-15E7D6BDADB1Q47626786-9F1E8143-26B6-4EE0-A337-EFEB2B614653Q47673299-7E808B6B-BF8D-4687-B752-9847B3D94F80Q48060040-FB300AFA-66FE-440E-8F8D-61124559B56CQ48260186-FA6A8F22-1691-4FF2-9411-F08F5113283DQ48565555-E6B88289-833B-4382-9764-A3BC9D435FFFQ48651395-00F93EAB-6BAA-414F-9613-3FF4944D7CD2Q49090622-9D49EA9A-ED5F-4B34-9C89-2BAC247D118E
P2860
Mapping FACT-P and EORTC QLQ-C30 to patient health status measured by EQ-5D in metastatic hormone-refractory prostate cancer patients.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Mapping FACT-P and EORTC QLQ-C ...... tory prostate cancer patients.
@en
Mapping FACT-P and EORTC QLQ-C ...... tory prostate cancer patients.
@nl
type
label
Mapping FACT-P and EORTC QLQ-C ...... tory prostate cancer patients.
@en
Mapping FACT-P and EORTC QLQ-C ...... tory prostate cancer patients.
@nl
prefLabel
Mapping FACT-P and EORTC QLQ-C ...... tory prostate cancer patients.
@en
Mapping FACT-P and EORTC QLQ-C ...... tory prostate cancer patients.
@nl
P2093
P1433
P1476
Mapping FACT-P and EORTC QLQ-C ...... tory prostate cancer patients.
@en
P2093
Darryl Sleep
Max H Farrell
Parvez Mulani
P304
P356
10.1111/J.1524-4733.2007.00195.X
P50
P577
2007-09-01T00:00:00Z